Related Experiment Video
Updated: Jan 2, 2026

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
Published on: April 5, 2018
Epigenetic signatures in overgrowth syndromes: Translational opportunities
Cheryl Cytrynbaum1,2,3, Sanaa Choufani3, Rosanna Weksberg1,2,3,4,5
1Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario.
Abstract:
In recent years, numerous overgrowth syndromes have been found to be caused by pathogenic DNA sequence variants in "epigenes," genes that encode proteins that function in epigenetic regulation. Epigenetic marks, including DNA methylation (DNAm), histone modifications and chromatin conformation, have emerged as a vital genome-wide regulatory mechanism that modulate the transcriptome temporally and spatially to drive normal developmental and cellular processes. Evidence suggests that epigenetic marks are layered and engage in crosstalk, in that disruptions of any one component of the epigenetic machinery impact the others. This interdependence of epigenetic marks underpins the recent identification of gene-specific DNAm signatures for a variety of disorders caused by pathogenic variants in epigenes. Here, we discuss the power of DNAm signatures with respect to furthering our understanding of disease pathophysiology, enhancing the efficacy of molecular diagnostics and identifying new targets for therapeutics of overgrowth syndromes. These findings highlight the promise of the field of epigenomics to provide unprecedented insights into disease mechanisms generating a host of opportunities to advance precision medicine.
More Related Videos
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Mitogens and the Cell Cycle
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...

